JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) Stock

Replimune Group (NASDAQ:REPL) had its price target increased by stock analysts at JPMorgan Chase & Co. from $16.00 to $18.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 42.41% from the company’s previous close.

A number of other equities research analysts have also commented on REPL. HC Wainwright raised their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. BMO Capital Markets lifted their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. Finally, Jefferies Financial Group lifted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $19.43.

Replimune Group Trading Down 4.5 %

Shares of NASDAQ:REPL opened at $12.64 on Wednesday. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The company has a quick ratio of 11.43, a current ratio of 11.43 and a debt-to-equity ratio of 0.14. The company’s fifty day simple moving average is $12.77 and its 200 day simple moving average is $11.96. The firm has a market cap of $973.47 million, a price-to-earnings ratio of -4.12 and a beta of 1.30.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). As a group, research analysts forecast that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Activity

In other news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sterling Capital Management LLC boosted its holdings in shares of Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock worth $26,000 after buying an additional 1,655 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Replimune Group by 696.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock worth $82,000 after buying an additional 5,922 shares during the period. Aster Capital Management DIFC Ltd boosted its holdings in shares of Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock worth $100,000 after buying an additional 8,183 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Replimune Group during the 4th quarter worth about $117,000. Finally, Quantinno Capital Management LP bought a new stake in shares of Replimune Group during the 4th quarter worth about $127,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.